Other (Income) Expense, Net (Details) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Component of Operating Income [Abstract]
Net gain on sale of certain early-stage drug discovery and development assets				$ 0	$ 0	$ (5,200)
Foreign currency loss (gain), net				2,991	(23,058)	(10,054)
Equity (earnings) loss from unconsolidated subsidiaries, net				(1,190)	3,217	(8,325)
Other-than-temporary impairment of equity investment		$ 18,900		0	18,869	0
Legal settlement				0	(12,500)	0
Costs associated with unused financing commitments	$ 64,300	$ 2,300	$ 11,800	0	78,352	0
Other miscellaneous, net				(2,139)	(1,189)	(8,745)
Other (income) expense, net				$ (338)	$ 63,691	$ (32,324)